Key result
Non-HDL-C and apoB detect high-risk dyslipidemia missed by LDL-C in hypertriglyceridemic diabetics, with non-HDL-C proving superior.
Why the study?
LDL cholesterol underestimates cholesterol burden in diabetic patients, and the impact of apoB or non-HDL-C on dyslipidemic classification in HbA1c-defined diabetic patients was unclear.
Does apolipoprotein B or non-HDL-C improve the detection of high-risk dyslipidemic phenotypes compared to LDL-C in HbA1c-defined diabetic patients?
Cross-Sectional
Yes
Does apolipoprotein B or non-HDL-C improve the detection of high-risk dyslipidemic phenotypes compared to LDL-C in HbA1c-defined diabetic patients?
Non-HDL-C is superior to apoB and LDL-C for identifying high-risk dyslipidemic phenotypes in hypertriglyceridemic diabetic patients.
Answers are grounded in this paper and cite their sources.
May enhance diabetic dyslipidemia phenotyping; leaves open outcome impact of apoB/non-HDL-C integration.
Low-density lipoprotein (LDL) cholesterol (LDL-C) always underestimates the true cholesterol burden in diabetic patients. We aimed to explore the impact of the inclusion of apolipoprotein B (apoB) or non-high-density lipoprotein (HDL) cholesterol (non-HDL-C), which are alternative markers of LDL-related risk, results in a better classification of glycated hemoglobin (HbA1c)-defined diabetic patients into different dyslipidemic phenotypes.We used data from the nationwide China Health and Nutrition Survey 2009 in which standardized HbA1c was measured.The prevalence of abnormal LDL using non-HDL-cholesterol (74.1%) was similar to the prevalence rate using LDL-C (75.2%), whereas the prevalence was relatively lower when using apoB (69.6%). In normotriglyceridemic HbA1c-defined diabetic patients, apoB and non-HDL-C were not superior to LDL-C in detecting abnormal LDL. However, in hypertriglyceridemic patients, apoB and non-HDL-C were superior to LDL-C for the detection of abnormal lipid levels, but apoB was not superior to non-HDL-C in detecting abnormal LDL in hypertriglyceridemic participants.Both apoB and non-HDL-C identify high-risk dyslipidemic phenotypes that are not detected by LDL-C in hypertriglyceridemic HbA1c-defined diabetic patients, with the superiority of non-HDL- C over apoB.
No takes yet. Share an insight, caveat, or question.
Xie et al. (2018) conducted a cross-sectional in HbA1c-defined diabetes. Apolipoprotein B (apoB) and non-HDL-C vs. LDL-C was evaluated on Prevalence of abnormal LDL. In hypertriglyceridemic diabetic patients, both apoB and non-HDL-C identified high-risk dyslipidemic phenotypes undetected by LDL-C, with non-HDL-C being superior to apoB.
Synapse has enriched 10 related papers. Consider them for comparative context: